Moloney Securities Asset Management LLC Purchases New Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Moloney Securities Asset Management LLC acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 904 shares of the company's stock, valued at approximately $374,000.

A number of other large investors have also added to or reduced their stakes in IDXX. Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in shares of IDEXX Laboratories by 400.0% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 500 shares of the company's stock worth $253,000 after purchasing an additional 400 shares during the period. Carnegie Investment Counsel bought a new position in shares of IDEXX Laboratories in the 3rd quarter worth $205,000. Procyon Advisors LLC raised its position in shares of IDEXX Laboratories by 2.2% in the 3rd quarter. Procyon Advisors LLC now owns 1,544 shares of the company's stock worth $780,000 after acquiring an additional 33 shares in the last quarter. Creative Planning raised its position in shares of IDEXX Laboratories by 2.6% in the 3rd quarter. Creative Planning now owns 24,436 shares of the company's stock worth $12,346,000 after acquiring an additional 614 shares in the last quarter. Finally, RDA Financial Network raised its position in shares of IDEXX Laboratories by 25.2% in the 3rd quarter. RDA Financial Network now owns 1,771 shares of the company's stock worth $895,000 after acquiring an additional 357 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares of the company's stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares of the company's stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,330 shares of company stock worth $6,161,276. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Price Performance

IDXX stock traded down $15.23 during mid-day trading on Friday, reaching $444.53. 553,751 shares of the company's stock were exchanged, compared to its average volume of 714,172. The company has a market cap of $36.40 billion, a price-to-earnings ratio of 41.66, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37. The stock's 50 day moving average is $430.77 and its 200 day moving average is $453.31. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 1.03. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39.

Analysts Set New Price Targets

Several brokerages recently issued reports on IDXX. Morgan Stanley reduced their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Wednesday, February 5th. Piper Sandler upped their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday. Barclays boosted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Finally, Bank of America upped their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.